Focused On-demand Library for ADP-ribosylation factor-like protein 2

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
P36404

UPID:
ARL2_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P36404; G3V184; Q9BUK8

BACKGROUND:
ADP-ribosylation factor-like protein 2 regulates key cellular mechanisms such as microtubule assembly, centrosome cohesion, and mitochondrial integrity. It is essential for cell cycle, secretory pathways, and nuclear functions, including the transcriptional activity of STAT3. Its activity is modulated by interaction with proteins like TBCD, influencing epithelial cell dynamics.

THERAPEUTIC SIGNIFICANCE:
Linked to the genetic condition Microcornea, rod-cone dystrophy, cataract, and posterior staphyloma 1, ADP-ribosylation factor-like protein 2's study offers insights into novel therapeutic avenues. Its critical cellular roles underscore the potential for targeted drug development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 7554 of 8789